High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)

Leukemia

Volumn 29, Issue 9, 2015, Pages 1928-1938

  Mohamedali, A M ^a,b   Gaken J ^a   Ahmed, M ^a,b   Malik, F ^a   Smith, A E ^a,b   Best, S ^a,b   Mian, S ^a   Gaymes, T ^a,b   Ireland, R ^b   Kulasekararaj, A G ^a,b   Mufti, G J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; CBL PROTEIN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; K RAS PROTEIN; LENALIDOMIDE; PROTEIN P53; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1;

5Q- SYNDROME; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD; BONE MARROW; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; COHORT ANALYSIS; CYTOGENETICS; FEMALE; GENE SEQUENCE; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; KARYOTYPE; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NONSENSE MUTATION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL; BLOOD CELL; BONE MARROW CELL; COPY NUMBER VARIATION; GENETIC ASSOCIATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEOTIDE SEQUENCE; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD CELLS; BONE MARROW; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOMICS; HUMANS; KARYOTYPE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84940791229     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.110     Document Type: Article

References (40)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification Of Tumours Of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer: Lyon, France, 2008, 439 pp.
2. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
3. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
5. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365-3373.
6. Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117: 4552-4560.
7. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
8. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
9. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
10. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44: 53-57.
11. Lindsley RC, Ebert BL. The biology and clinical impact of genetic lesions in myeloid malignancies. Blood 2013; 122: 3741-3748.
12. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
13. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275-1282.
14. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943-2964.
15. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
16. Braulke F, Platzbecker U, Muller-Thomas C, Gotze K, Germing U, Brummendorf TH et al. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica 2014; 100: 205-213.
17. Mohamedali AM, Alkhatabi H, Kulasekararaj A, Shinde S, Mian S, Malik F et al. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood 2013; 122: 567-570.
18. Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali AM, Lea NC et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica 2013; 98: 1058-1066.
19. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-1181.
20. Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 2013; 121: 260-269.
21. Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 2013; 122: 3169-3177.
22. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
23. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
24. Fernandez-Mercado M, Pellagatti A, Di Genua C, Larrayoz MJ, Winkelmann N, Aranaz P et al. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. Br J Haematol 2013; 163: 235-239.
25. Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W et al. Wholeexome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011; 118: 6153-6163.
26. Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971-1979.
27. Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
28. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
29. Langemeijer SMC, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
30. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
31. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012; 26: 101-105.
32. Rajala HLM, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013; 121: 4541-4550.
33. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
34. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153-1158.
35. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478.
36. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 37: 2477-2487.
37. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487.
38. Sinha S, Thomas D, Yu L, Gentles A, Jung N, Corces-Zimmerman MR et al. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood 2014; 125: 316-326.
39. Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C et al. IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition. Blood 2014; 125: 296-303.
40. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009; 114: 4847-4858.